A5046259040- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Frailty in Older Adults
- Prostate Cancer Treatment and Research
- Inflammatory Biomarkers in Disease Prognosis
- Breast Cancer Treatment Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Nutrition and Health in Aging
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Prostate Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- Management of metastatic bone disease
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
Associazione Italiana Di Oncologia Medica
2023-2024
Ospedale di Sanremo
2013-2023
Boréa (Sweden)
2015
Azienda Sanitaria Locale Roma 3
2010
Medica (Italy)
2000-2003
Istituto Nazionale di Riposo e Cura per Anziani
2002
Presidio Ospedaliero
2002
Centro di Riferimento Oncologico
1999-2002
Istituti di Ricovero e Cura a Carattere Scientifico
2002
Azienda Sanitaria Locale CN2
2000
PURPOSE: To appraise the performance of Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (≥ 65 years) and to evaluate whether it could add further information with respect Eastern Cooperative Oncology Group status (PS). PATIENTS AND METHODS: We studied 363 (195 males, 168 females; median age, 72 solid (n = 271) or hematologic 92) tumors. In addition PS, their physical function was assessed by means activity daily living (ADL) instrumental activities (IADL) scales....
PURPOSE: To appraise the performance of Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (≥ 65 years) and to evaluate whether it could add further information with respect Eastern Cooperative Oncology Group status (PS). PATIENTS AND METHODS: We studied 363 (195 males, 168 females; median age, 72 solid (n = 271) or hematologic 92) tumors. In addition PS, their physical function was assessed by means activity daily living (ADL) instrumental activities (IADL) scales....
Abstract Background In a disease like unresectable hepatocellular carcinoma, overall survival is an inadequate outcome measure for evaluating the effectiveness of treatments given high risk death from liver failure. There unmet need reliable alternative end points clinical trials and daily practice. To evaluate treatment response in patients with or metastatic carcinoma (mHCC), imaging‐related are often used, whereas serologic have been developed serum alpha‐fetoprotein levels >20 ng/mL....
Of 683 (16.1 %) consecutive patients investigated from October 1984 to December 1985, 110 had various malignant tumors and secondary bone involvement. In 82 of (74.5%), the primary tumor was located in breast, percentage clinical radiographic objective responses (OR) their lesions (42.7% 22.8%, respectively) higher than for cancer other sites (clinical OR, 21.4%; 15.8%). The average survival time breast 87.4 months, or 38 months diagnosis metastases. with metastases, 60 (54.5%) spinal OR...